United States - English - NLM (National Library of Medicine)

alvogen inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance. hypersensitivity to dapsone and/or its derivatives.

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance. hypersensitivity to dapsone and/or its derivatives.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

United States - English - NLM (National Library of Medicine)

avkare, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

United States - English - NLM (National Library of Medicine)

nostrum laboratories, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 100 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance. hypersensitivity to dapsone and/or its derivatives.

United States - English - NLM (National Library of Medicine)

pacific pharma, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 50 mg in 1 g - dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on dapsone gel, 5% in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4%

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; silicon dioxide; microcrystalline cellulose - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 25 mg - tablet, uncoated - excipient ingredients: silicon dioxide; magnesium stearate; microcrystalline cellulose; maize starch - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.